Anti‐immobility activity of different antidepressant drugs using the tail suspension test in normal or reserpinized mice
- 1 July 1993
- journal article
- research article
- Published by Wiley in Fundamental & Clinical Pharmacology
- Vol. 7 (5), 219-226
- https://doi.org/10.1111/j.1472-8206.1993.tb00235.x
Abstract
Summary— The tail suspension test is a screening procedure recently used in mice to detect antidepressant activity of drugs. The ability of amine re‐uptake inhibitors to decrease immobility in non‐reserpinized and in reserpinized mice was studied. Reserpine (4 mg/kg ip) was injected 4 h previously. Anti‐depressants were administered ip, 60 min before tail suspension. Animal activity was recorded for 6 min. Preferential serotonin re‐uptake blockers (fluoxetine, fluvoxamine, clomipramine) were poorly active in non‐reserpinized mice and inactive in reserpine‐treated mice. Noradrenergic drugs (desipramine, demexiptiline, viloxazine) were more efficient in reserpinized than in non‐reserpinized mice. The mixed serotonin‐ noradrenaline re‐uptake inhibitor (imipramine) shows an activity which should be considered between serotonin re‐uptake inhibitors and noradrenaline re‐uptake inhibitors. DA re‐uptake inhibitors (amineptine, GBR 12909) exhibited the highest anti‐immobility effect in non reserpinized animals but were of low efficacy after reserpine treatment. Amphetamine differed from dopamine re‐uptake inhibitors by its better activity in reserpinized animals. Moreover, it was the only drug showing an equal anti‐immobility effect in non reserpinized and reserpinized mice because the dose of 8 mg/kg of amphetamine reduced immobility in reserpinised mice with the same intensity as the dose of 4 mg/kg in non reserpinised mice whereas no other drugs tested in this study achieved the same effect. Comparison of anti‐immobility activities of putative antidepressants in non‐pre‐treated and in reserpine‐pre‐treated mice, using the tail suspension test, may be useful to discriminate amphetamines from antidepressant drugs and to differentiate between categories of amine re‐uptake blockers.Keywords
This publication has 36 references indexed in Scilit:
- The dopamine uptake inhibitor GBR 12909: selectivity and molecular mechanism of actionEuropean Journal of Pharmacology, 1989
- Repeated treatment with amitriptyline reduces immobility in the behavioural ‘despair’ test in rats by activating dopaminergic and β-adrenergic mechanismsJournal of Pharmacy and Pharmacology, 1985
- Review of the animal pharmacology and pharmacokinetics of fluvoxamine.British Journal of Clinical Pharmacology, 1983
- Biochemical and pharmacological studies on amineptine (S 1694) and (+)-amphetamine in the ratJournal of Pharmacy and Pharmacology, 1977
- FLUVOXAMINE, A SPECIFIC 5‐HYDROXYTRYPTAMINE UPTAKE INHIBITORBritish Journal of Pharmacology, 1977
- Effects of viloxazine, an antidepressant agent, on biogenic amine uptake mechanisms and related activitiesCanadian Journal of Physiology and Pharmacology, 1976
- Dopamine and noradrenaline receptor stimulation: Reversal of reserpine-induced suppression of motor activityPsychopharmacology, 1973
- Effects of amphetamine on the turnover rate of brain catecholamines and motor activityBritish Journal of Pharmacology, 1972
- THE CATECHOLAMINE HYPOTHESIS OF AFFECTIVE DISORDERS: A REVIEW OF SUPPORTING EVIDENCEAmerican Journal of Psychiatry, 1965
- A simple screening procedure for imipramine-like antidepressant agentsLife Sciences, 1963